What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 Debate happening now:
📺⚕️Telemedicine: Salvation or necessary evil?
@RheumNow
Dr. Rachel Tate uptoTate
3 years 6 months ago
Older age, HTN, dyslipidemia, CKD, cancer hx, and chronic liver disease co-morbidities increased risk of COVID19 severity. PMR was the only R-IMID identified and RTX tx also increased risk of severe COVID19. #EULAR2022 POS0203 @RheumNow https://t.co/TnhRnlWkX2
Dr. Rachel Tate uptoTate
3 years 6 months ago
#EULAR2022 POS0196 found 9% of post-COVID19 patients developed MSK symptoms. @RheumNow https://t.co/YFT83TjXFL
Richard Conway RichardPAConway
3 years 6 months ago
Dr Yeoh @SuAnnYeoh1 @rheum_covid Factors assoc severe COVID outcomes in IIM. Age, male, high disease activity, 2+ comorbidities, pred>7.5mg, RTX, assoc hospitalisation or death @RheumNow #EULAR2022 OP0252 https://t.co/PvCeSX8UvF https://t.co/RaISpeUNsH
Dr. Rachel Tate uptoTate
3 years 6 months ago
#EULAR2022 POS0199 showed marked decrease in SARS-CoV2 IgG ab 6 months after initial two dose vaccines. @RheumNow https://t.co/lZdWQUqFvf
Janet Pope Janetbirdope
3 years 6 months ago
Are JAKi fulfilling their promises in RA? H Schulz-Koops said a survey showed rheumatologists wanted effective fast acting Rx that could be used as monotherapy. @eular_org #EULAR2022 @RheumNow https://t.co/Gdel9YnAzA
TheDaoIndex KDAO2011
3 years 6 months ago
More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf
TheDaoIndex KDAO2011
3 years 6 months ago
Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#OP0252 #EULAR2022 Dr Yeoh presented data from Global Rheum Alliance of >300 pts with myositis. 13% died. Usual suspects re: Factors assoc with poor #COVID outcome: age, active disease,on steroid,male and RTX exposure. Be interesting to see longer followup post-booster @RheumNow https://t.co/F7qaee5ADK
Janet Pope Janetbirdope
3 years 6 months ago
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/u9KkZrUKGo
TheDaoIndex KDAO2011
3 years 6 months ago
#PEARLS by Dr. Werth:
1. anti-malarials only work 50% of time for cutaneous lupus (CLE).
2. AZP is not as effective as MTX or MMF for #CLE
3. Consider RTX refractory #bullous lupus #EULAR2022 @rheumnow https://t.co/6FPJEGWioJ
Aurelie Najm AurelieRheumo
3 years 6 months ago
VIGIBASE registry RA
39000+ pts JAKi and 231000+ pts TNFi
*No increase in MACEs with JAKi 1.4% vs. 0.9%
*JAKi Increase in DVT RR 3.99
and PE RR 3.5
adjusted on age and sex
@RheumNow #OP0268 #EULAR2022 #Lupus https://t.co/hiAvKctgky
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022
Rebuttal!
💻⚕️
Telemedicine improves patient-doctor relationship
Supplements F2F visits, making them more efficient
Patients are communicating, texting all the time
Can AI help improve early pt communication?
@ChristianDejaco
@RheumNow
Janet Pope Janetbirdope
3 years 6 months ago
Some / most of promises of #JAKi are fulfilled. Efficacy, adherence = on mono vs combination Rx with MTX. But some emerging safety issues. NK cells reduce inflammation of NK cells on fibroblasts re other MOA. @eular #EULAR2022 @RheumNow The promise of #JAKi I RA https://t.co/8Ry3vVMyzO
Richard Conway RichardPAConway
3 years 6 months ago
Gilbert et al. RA assoc increased risk hospitalisation or death from COVID-19 1.53 (1.20, 1.94). RA-ILD assoc even greater risk hospitalisation or death multivariable HR 2.84 [95% CI 1.64-4.91] @RheumNow #EULAR2022 OP0251 https://t.co/h1jzAV6xNR https://t.co/7E1EzAKCDv
Poster Hall